Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 873

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

Open access
Fassnacht, Martin, Terzolo, Massimo, Allolio, Bruno, Baudin, Eric, Haak, Harm, Berruti, Alfredo, Welin, Staffan, Schade-Brittinger, Carmen, Lacroix, André, Jarzab, Barbara, Sorbye, Halfdan, Torpy, David J., Stepan, Vinzenz, Schteingart, David E., Arlt, Wiebke, Kroiss, Matthias, Leboulleux, Sophie, Sperone, Paola, Sundin, Anders, Hermsen, Ilse, Hahner, Stefanie, Willenberg, Holger S., Tabarin, Antoine, Quinkler, Marcus, de la Fouchardière, Christelle, Schlumberger, Martin, Mantero, Franco, Weismann, Dirk, Beuschlein, Felix, Gelderblom, Hans, Wilmink, Hanneke, Sender, Monica, Edgerly, Maureen, Kenn, Werner, Fojo, Tito, Müller, Hans-Helge, Skogseid, Britt·2012·New England Journal of Medicine
DOI 10.1056/nejmoa1200966
Open this paper in CoChat — free account

Abstract

BACKGROUND: Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment. METHODS: We randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg per square meter on day 1), and cisplatin (40 mg per square meter on days 3 and 4) (EDP) every 4 weeks or streptozocin (streptozotocin) (1 g on days 1 to 5 in cycle 1; 2 g on day 1 in subsequent cycles) every 3 weeks. Patients with disease progression received the alternative regimen as second-line therapy. The primary end point was overall survival. RESULTS: For first-line therapy, patients in the EDP-mitotane group had a significantly higher response rate than those in the streptozocin-mitotane group (23.2% vs. 9.2%, P<0.001) and longer median progression-free survival (5.0 months vs. 2.1 months; hazard ratio, 0.55; 95% confidence interval [CI], 0.43 to 0.69; P<0.001); there was no significant between-group difference in overall survival (14.8 months and 12.0 months, respectively; hazard ratio, 0.79; 95% CI, 0.61 to 1.02; P=0.07). Among the 185 patients who received the alternative regimen as second-line therapy, the median duration of progression-free survival was 5.6 months in the EDP-mitotane group and 2.2 months in the streptozocin-mitotane group. Patients who did not receive the alternative second-line therapy had better overall survival with first-line EDP plus mitotane (17.1 month) than with streptozocin plus mitotane (4.7 months). Rates of serious adverse events did not differ significantly between treatments. CONCLUSIONS: Rates of response and progression-free survival were significantly better with EDP plus mitotane than with streptozocin plus mitotane as first-line therapy, with similar rates of toxic events, although there was no significant difference in overall survival. (Funded by the Swedish Research Council and others; FIRM-ACT ClinicalTrials.gov number, NCT00094497.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1200966

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 873

Metadata

Authors
Fassnacht, M., Terzolo, M., Allolio, B., Baudin, E., Haak, H., Berruti, A., Welin, S., Schade-Brittinger, C., Lacroix, A., Jarzab, B., Sorbye, H., Torpy, D. J., Stepan, V., Schteingart, D. E., Arlt, W., Kroiss, M., Leboulleux, S., Sperone, P., Sundin, A., Hermsen, I., Hahner, S., Willenberg, H. S., Tabarin, A., Quinkler, M., de la Fouchardière, C., Schlumberger, M., Mantero, F., Weismann, D., Beuschlein, F., Gelderblom, H., Wilmink, H., Sender, M., Edgerly, M., Kenn, W., Fojo, T., Müller, H.-H., & Skogseid, B.
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2012-06-07
Volume
366
Issue
23
Pages
2189-2197
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa1200966
OpenAlex
W1967352082
Cited by
873
References
33
FWCI
62.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination Chemotherapy in Advanced Adrenocortical Carcinoma. https://app.cochat.ai/papers/10.1056/nejmoa1200966
The paper
Fassnacht, M., Terzolo, M., Allolio, B., Baudin, E., Haak, H., Berruti, A., Welin, S., Schade-Brittinger, C., Lacroix, A., Jarzab, B., Sorbye, H., Torpy, D. J., Stepan, V., Schteingart, D. E., Arlt, W., Kroiss, M., Leboulleux, S., Sperone, P., Sundin, A., . . . Skogseid, B. (2012). Combination Chemotherapy in Advanced Adrenocortical Carcinoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1200966

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.